Literature DB >> 27151990

C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas.

Rebeca Manso1, Carmen Bellas2, Paloma Martín-Acosta2, Manuela Mollejo3, Javier Menárguez4, Federico Rojo1, Pilar Llamas5, Miguel A Piris6, Socorro M Rodríguez-Pinilla7.   

Abstract

Entities:  

Keywords:  C-MYC; GATA3; PTCL

Mesh：

Substances：

Year:  2016        PMID： 27151990      PMCID： PMC4967584          DOI： 10.3324/haematol.2016.143768

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.

Authors:  Javeed Iqbal; George Wright; Chao Wang; Andreas Rosenwald; Randy D Gascoyne; Dennis D Weisenburger; Timothy C Greiner; Lynette Smith; Shuangping Guo; Ryan A Wilcox; Bin Tean Teh; Soon Thye Lim; Soon Yong Tan; Lisa M Rimsza; Elaine S Jaffe; Elias Campo; Antonio Martinez; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; German Ott; Eva Geissinger; Philippe Gaulard; Pier Paolo Piccaluga; Stefano A Pileri; Wing Y Au; Shigeo Nakamura; Masao Seto; Francoise Berger; Laurence de Leval; Joseph M Connors; James Armitage; Julie Vose; Wing C Chan; Louis M Staudt
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

2.  Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach.

Authors:  Christoph Thorns; Boris Bastian; Daniel Pinkel; Ritu Roydasgupta; Jane Fridlyand; Hartmut Merz; Manuela Krokowski; Heinz-Wolfram Bernd; Alfred Christian Feller
Journal:  Genes Chromosomes Cancer       Date:  2007-01       Impact factor: 5.006

3.  C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC.

Authors:  Hiroshi Moritake; Hidemi Shimonodan; Kousuke Marutsuka; Sachiyo Kamimura; Hitomi Kojima; Hiroyuki Nunoi
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

4.  Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas.

Authors:  Marta Cuadros; Sandeep S Dave; Elaine S Jaffe; Emiliano Honrado; Roger Milne; Javier Alves; Jose Rodríguez; Magdalena Zajac; Javier Benitez; Louis M Staudt; Beatriz Martinez-Delgado
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

5.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

6.  Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.

Authors:  Jan Piet van Hamburg; Marjolein J W de Bruijn; Gemma M Dingjan; H Berna Beverloo; Hans Diepstraten; Kam-Wing Ling; Rudi W Hendriks
Journal:  Mol Immunol       Date:  2008-05-08       Impact factor: 4.407

7.  MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.

Authors:  Z-X Yan; L-L Wu; K Xue; Q-L Zhang; Y Guo; M Romero; C Leboeuf; A Janin; S-J Chen; L Wang; W-L Zhao
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

8.  GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

Authors:  Tianjiao Wang; Andrew L Feldman; David A Wada; Ye Lu; Avery Polk; Robert Briski; Kay Ristow; Thomas M Habermann; Dafydd Thomas; Steven C Ziesmer; Linda E Wellik; Thomas M Lanigan; Thomas E Witzig; Mark R Pittelkow; Nathanael G Bailey; Alexandra C Hristov; Megan S Lim; Stephen M Ansell; Ryan A Wilcox
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas.

Authors:  S M Rodríguez-Pinilla; M E C Sánchez; J Rodríguez; J F García; B Sánchez-Espiridión; L F Lamana; G Sosa; J C Rivero; J Menárguez; I B Gómez; F I Camacho; P R Guillen; C P S Orduña; G Rodríguez; C Barrionuevo; R Franco; M Mollejo; J F Marco; R D de Otazu; M A Piris
Journal:  Blood Cancer J       Date:  2013-04-19       Impact factor: 11.037

10.  GATA-3 controls the maintenance and proliferation of T cells downstream of TCR and cytokine signaling.

Authors:  Yunqi Wang; Ichiro Misumi; Ai-Di Gu; T Anthony Curtis; Lishan Su; Jason K Whitmire; Yisong Y Wan
Journal:  Nat Immunol       Date:  2013-05-26       Impact factor: 25.606
View more
  13 in total

1.  A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.

Authors:  Philip S Boonstra; Avery Polk; Noah Brown; Alexandra C Hristov; Nathanael G Bailey; Mark S Kaminski; Tycel Phillips; Sumana Devata; Tera Mayer; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2017-09-25       Impact factor: 10.047

Review 2.  The role of aurora A and polo-like kinases in high-risk lymphomas.

Authors:  Carlos Murga-Zamalloa; Kedar V Inamdar; Ryan A Wilcox
Journal:  Blood Adv       Date:  2019-06-11

Review 3.  GATA-3 in T-cell lymphoproliferative disorders.

Authors:  Carlos Murga-Zamalloa; Ryan A Wilcox
Journal:  IUBMB Life       Date:  2019-07-17       Impact factor: 3.885

Review 4.  Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.

Authors:  Mamiko Sakata-Yanagimoto; Kota Fukumoto; Kennosuke Karube; Shigeru Chiba
Journal:  J Clin Exp Hematop       Date:  2021-03-15

5.  TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer.

Authors:  Xiaoting Jia; Zhijie Zhang; Kai Luo; Guopei Zheng; Minying Lu; Ying Song; Hao Liu; Huisi Qiu; Zhimin He
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

6.  Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.

Authors:  Rebeca Manso; Julia González-Rincón; Manuel Rodríguez-Justo; Giovanna Roncador; Sagrario Gómez; Margarita Sánchez-Beato; Miguel A Piris; Socorro M Rodríguez-Pinilla
Journal:  Oncotarget       Date:  2018-03-01

7.  Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.

Authors:  Craig R Soderquist; Nupam Patel; Vundavalli V Murty; Shane Betman; Nidhi Aggarwal; Ken H Young; Luc Xerri; Rebecca Leeman-Neill; Suzanne K Lewis; Peter H Green; Susan Hsiao; Mahesh M Mansukhani; Eric D Hsi; Laurence de Leval; Bachir Alobeid; Govind Bhagat
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

8.  Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.

Authors:  Takahisa Yamashita; Morihiro Higashi; Shuji Momose; Akiko Adachi; Toshiki Watanabe; Yuka Tanaka; Michihide Tokuhira; Masahiro Kizaki; Jun-Ichi Tamaru
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

9.  Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.

Authors:  Yasuhito Mihashi; Shoichi Kimura; Hiromi Iwasaki; Yumi Oshiro; Yasushi Takamatsu; Shigeto Kawauchi; Shohei Shimajiri; Kenji Ishizuka; Morishige Takeshita
Journal:  Diagn Pathol       Date:  2021-11-06       Impact factor: 2.644

10.  Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma.

Authors:  Martina Magni; Chiara Paolizzi; Chiara Monfrini; Cristina Vella; Paolo Corradini; Cristiana Carniti
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.